{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:40:04Z","timestamp":1754044804400,"version":"3.41.2"},"reference-count":116,"publisher":"Elsevier","isbn-type":[{"value":"9780443187223","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/b978-0-443-18722-3.00035-9","type":"book-chapter","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T09:47:51Z","timestamp":1754041671000},"page":"919-928","source":"Crossref","is-referenced-by-count":0,"title":["Epigenetics in doxorubicin cardiotoxicity"],"prefix":"10.1016","author":[{"given":"Luciana L.","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Rafael","family":"Silveira","sequence":"additional","affiliation":[]},{"given":"Paulo J.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Cunha-Oliveira","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/B978-0-443-18722-3.00035-9_bib1","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2006.08.005","article-title":"Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study","volume":"42","author":"van Dalen","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5669","key":"10.1016\/B978-0-443-18722-3.00035-9_bib2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/bmj.3.5669.503","article-title":"Clinical evaluation of adriamycin, a new antitumour antibiotic","volume":"3","author":"Bonadonna","year":"1969","journal-title":"Br Med J"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib3","first-page":"2572","article-title":"Phase I and preliminary phase II evaluation of adriamycin (NSC 123127)","volume":"30","author":"Bonadonna","year":"1970","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/B978-0-443-18722-3.00035-9_bib4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/bit.260110607","article-title":"Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius","volume":"11","author":"Arcamone","year":"1969","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrclinonc.2013.195","article-title":"Treatment-related cardiotoxicity in survivors of childhood cancer","volume":"10","author":"Lipshultz","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","article-title":"Doxorubicin: nanotechnological overviews from bench to bedside","volume":"22","author":"Cagel","year":"2017","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/B978-0-443-18722-3.00035-9_bib8","first-page":"2467","article-title":"Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex","volume":"61","author":"Kiyomiya","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib9","first-page":"84","article-title":"Doxorubicin, DNA torsion, and chromatin dynamics","volume":"1845","author":"Yang","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/B978-0-443-18722-3.00035-9_bib10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbrc.2008.11.059","article-title":"Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs","volume":"378","author":"Ashley","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/B978-0-443-18722-3.00035-9_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(02)00715-5","article-title":"Culprit and victim \u2013 DNA topoisomerase II","volume":"3","author":"Kellner","year":"2002","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/B978-0-443-18722-3.00035-9_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0022-3565(24)38772-5","article-title":"Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines","volume":"296","author":"Bellarosa","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib14","first-page":"4543","article-title":"Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase","volume":"43","author":"Doroshow","year":"1983","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/B978-0-443-18722-3.00035-9_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","article-title":"Oxidative stress injury in doxorubicin-induced cardiotoxicity","volume":"307","author":"Songbo","year":"2019","journal-title":"Toxicol Lett"},{"issue":"11","key":"10.1016\/B978-0-443-18722-3.00035-9_bib17","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2013.201","article-title":"Topoisomerase 2beta: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","volume":"95","author":"Vejpongsa","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/B978-0-443-18722-3.00035-9_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib21","series-title":"Mitochondrial Dysfunction by Drug and Environmental Toxicants. II","first-page":"593","article-title":"Mitochondrial toxicity induced by chemotherapeutic drugs","author":"Ferreira","year":"2018"},{"issue":"6","key":"10.1016\/B978-0-443-18722-3.00035-9_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00685796","article-title":"Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry","volume":"36","author":"Dobbs","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/B978-0-443-18722-3.00035-9_bib23","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience","volume":"15","author":"Krischer","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/B978-0-443-18722-3.00035-9_bib24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1989.7.5.560","article-title":"Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer","volume":"7","author":"Henderson","year":"1989","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2217\/pgs.12.205","article-title":"Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity","volume":"14","author":"Jensen","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1517\/17425255.2011.610180","article-title":"Pharmacogenetics of genes across the doxorubicin pathway","volume":"7","author":"Jamieson","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib27","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","article-title":"Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol","volume":"85","author":"Olson","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib28","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1124\/dmd.108.022251","article-title":"Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver","volume":"36","author":"Kassner","year":"2008","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"13","key":"10.1016\/B978-0-443-18722-3.00035-9_bib29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes \u2013 a report from the children\u2019s oncology group","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.108.024547","article-title":"Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors","volume":"37","author":"Gonzalez-Covarrubias","year":"2009","journal-title":"Drug Metab Dispos Biol fate Chem"},{"issue":"24","key":"10.1016\/B978-0-443-18722-3.00035-9_bib31","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/B978-0-443-18722-3.00035-9_bib32","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/B978-0-443-18722-3.00035-9_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1389200013338243","article-title":"Contribution of specific transport systems to anthracycline transport in tumor and normal cells","volume":"2","author":"Nagasawa","year":"2001","journal-title":"Curr Drug Metab"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428190903177212","article-title":"Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood","volume":"50","author":"Rajic","year":"2009","journal-title":"Leuk Lymph"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib35","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/cncr.23534","article-title":"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer","volume":"112","author":"Blanco","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib36","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/j.1349-7006.2008.00903.x","article-title":"CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients","volume":"99","author":"Lal","year":"2008","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/B978-0-443-18722-3.00035-9_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-016-2979-9","article-title":"Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription","volume":"77","author":"Ye","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1476-4598-9-68","article-title":"DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response","volume":"9","author":"Dejeux","year":"2010","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/B978-0-443-18722-3.00035-9_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174227","article-title":"Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells","volume":"12","author":"Chang","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1078-0432.CCR-08-0166","article-title":"DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy","volume":"15","author":"Hartmann","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/B978-0-443-18722-3.00035-9_bib41","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/blood-2017-03-775569","article-title":"SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia","volume":"130","author":"Mar","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/B978-0-443-18722-3.00035-9_bib42","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.bbadis.2017.07.030","article-title":"Berberine-induced cardioprotection and Sirt3 modulation in doxorubicin-treated H9c2 cardiomyoblasts","volume":"1863","author":"Coelho","year":"2017","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/B978-0-443-18722-3.00035-9_bib43","doi-asserted-by":"crossref","first-page":"H962","DOI":"10.1152\/ajpheart.00832.2015","article-title":"Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice","volume":"310","author":"Pillai","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"10.1016\/B978-0-443-18722-3.00035-9_bib44","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1093\/nar\/gkaa214","article-title":"Deacetylase-independent function of SIRT6 couples GATA4 transcription factor and epigenetic activation against cardiomyocyte apoptosis","volume":"48","author":"Peng","year":"2020","journal-title":"Nucl Acids Res"},{"issue":"669","key":"10.1016\/B978-0-443-18722-3.00035-9_bib45","doi-asserted-by":"crossref","first-page":"eabm3565","DOI":"10.1126\/scitranslmed.abm3565","article-title":"TRIM35-mediated degradation of nuclear PKM2 destabilizes GATA4\/6 and induces P53 in cardiomyocytes to promote heart failure","volume":"14","author":"Lorenzana-Carrillo","year":"2022","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/B978-0-443-18722-3.00035-9_bib46","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.lfs.2013.10.013","article-title":"The role of autophagy in doxorubicin-induced cardiotoxicity","volume":"93","author":"Dirks-Naylor","year":"2013","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/B978-0-443-18722-3.00035-9_bib47","doi-asserted-by":"crossref","first-page":"e3018","DOI":"10.1038\/cddis.2017.410","article-title":"Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1\/LKB1\/AMPK pathway","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2015.03.438","article-title":"SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells","volume":"189","author":"De Angelis","year":"2015","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/B978-0-443-18722-3.00035-9_bib49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/cvr\/cvr022","article-title":"Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53","volume":"90","author":"Zhang","year":"2011","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib50","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.freeradbiomed.2007.03.007","article-title":"Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury","volume":"42","author":"Daosukho","year":"2007","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib51","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10637-010-9542-z","article-title":"The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity","volume":"30","author":"Tarasenko","year":"2012","journal-title":"Invest N Drugs"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12012-015-9327-x","article-title":"Role of DNA Methylation on the expression of the anthracycline metabolizing enzyme AKR7A2 in human heart","volume":"16","author":"Hoefer","year":"2016","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.taap.2014.10.006","article-title":"Early biomarkers of doxorubicin-induced heart injury in a mouse model","volume":"281","author":"Desai","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib54","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1007\/s00204-016-1668-0","article-title":"MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes","volume":"90","author":"Chaudhari","year":"2016","journal-title":"Arch Toxicol"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canlet.2021.03.018","article-title":"Long non-coding RNAs in the doxorubicin resistance of cancer cells","volume":"508","author":"Ashrafizaveh","year":"2021","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib56","first-page":"435","article-title":"Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K\/AKT\/mTOR signaling pathway","volume":"18","author":"Li","year":"2019","journal-title":"Exp Ther Med"},{"issue":"38","key":"10.1016\/B978-0-443-18722-3.00035-9_bib57","doi-asserted-by":"crossref","first-page":"64273","DOI":"10.18632\/oncotarget.19604","article-title":"LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib58","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/iub.2075","article-title":"LncRNA LOXL1-AS1\/miR-let-7a-5p\/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells","volume":"71","author":"Bai","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib59","article-title":"The IncRNA BORG: a novel inducer of TNBC metastasis, chemoresistance, and disease recurrence","volume":"5","author":"Gooding","year":"2019","journal-title":"J Cancer Metast Treat"},{"issue":"10","key":"10.1016\/B978-0-443-18722-3.00035-9_bib60","doi-asserted-by":"crossref","first-page":"17699","DOI":"10.1002\/jcb.29036","article-title":"HANR promotes lymphangiogenesis of hepatocellular carcinoma via secreting miR-296 exosome and regulating EAG1\/VEGFA signaling in HDLEC cells","volume":"120","author":"Shi","year":"2019","journal-title":"J Cell Biochem"},{"issue":"5","key":"10.1016\/B978-0-443-18722-3.00035-9_bib61","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1159\/000484116","article-title":"LncRNA HANR promotes tumorigenesis and increase of chemoresistance in hepatocellular carcinoma","volume":"43","author":"Xiao","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib62","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"Jama"},{"issue":"3","key":"10.1016\/B978-0-443-18722-3.00035-9_bib63","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12012-007-0026-0","article-title":"Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment","volume":"7","author":"Berthiaume","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tox.2017.08.011","article-title":"Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity","volume":"390","author":"Ferreira","year":"2017","journal-title":"Toxicology"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib65","first-page":"239","article-title":"Cardiac stem cells and progenitors: developmental biology and therapeutic challenges","volume":"117","author":"Parmacek","year":"2006","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib66","first-page":"1","article-title":"Endogenous cardiac stem cells for the treatment of heart failure","volume":"6","author":"Fuentes","year":"2013","journal-title":"Stem Cell Clon Adv Appl"},{"issue":"4","key":"10.1016\/B978-0-443-18722-3.00035-9_bib67","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12012-012-9177-8","article-title":"Differentiation-dependent doxorubicin toxicity on H9c2 cardiomyoblasts","volume":"12","author":"Branco","year":"2012","journal-title":"Cardiovasc Toxicol"},{"issue":"4","key":"10.1016\/B978-0-443-18722-3.00035-9_bib68","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fca.12.44","article-title":"Cardiotoxicity in childhood cancer survivors: strategies for prevention and management","volume":"8","author":"Harake","year":"2012","journal-title":"Fut Cardiol"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0002-8703(97)70205-9","article-title":"Cardiovascular responses to dynamic submaximal exercise in children previously treated with anthracycline","volume":"133","author":"Johnson","year":"1997","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1124\/pr.54.1.101","article-title":"Mitochondria as a pharmacological target","volume":"54","author":"Szewczyk","year":"2002","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib71","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0005-2728(99)00011-0","article-title":"Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration","volume":"1411","author":"Serrano","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/B978-0-443-18722-3.00035-9_bib72","doi-asserted-by":"crossref","first-page":"e38867","DOI":"10.1371\/journal.pone.0038867","article-title":"Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific","volume":"7","author":"Pereira","year":"2012","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/B978-0-443-18722-3.00035-9_bib73","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/0006-2952(80)90050-7","article-title":"Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity","volume":"29","author":"Goormaghtigh","year":"1980","journal-title":"Biochem Pharmacol"},{"issue":"2\u20133","key":"10.1016\/B978-0-443-18722-3.00035-9_bib74","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0301-4622(90)80012-V","article-title":"Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity","volume":"35","author":"Goormaghtigh","year":"1990","journal-title":"Biophys Chem"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0378-1119(01)00814-9","article-title":"Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage","volume":"286","author":"Paradies","year":"2002","journal-title":"Gene"},{"issue":"3","key":"10.1016\/B978-0-443-18722-3.00035-9_bib76","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0005-2728(87)90236-2","article-title":"Effects of adriamycin on respiratory chain activities in mitochondria from rat liver, rat heart and bovine heart. Evidence for a preferential inhibition of complex III and IV","volume":"892","author":"Nicolay","year":"1987","journal-title":"Biochimica et biophysica acta"},{"issue":"52","key":"10.1016\/B978-0-443-18722-3.00035-9_bib77","doi-asserted-by":"crossref","first-page":"52873","DOI":"10.1074\/jbc.M308366200","article-title":"Cardiolipin stabilizes respiratory chain supercomplexes","volume":"278","author":"Pfeiffer","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib78","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.chemphyslip.2013.10.012","article-title":"Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes","volume":"179","author":"Mileykovskaya","year":"2014","journal-title":"Chem Phys lipids"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mito.2016.07.005","article-title":"Cardiac cytochrome c and cardiolipin depletion during anthracycline-induced chronic depression of mitochondrial function","volume":"30","author":"Pereira","year":"2016","journal-title":"Mitochondrion"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10565-006-0140-y","article-title":"Adriamycin-induced oxidative mitochondrial cardiotoxicity","volume":"23","author":"Berthiaume","year":"2007","journal-title":"Cell Biol Toxicol"},{"issue":"7","key":"10.1016\/B978-0-443-18722-3.00035-9_bib81","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1016\/S0021-9258(17)35747-2","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical","volume":"261","author":"Doroshow","year":"1986","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12012-007-0008-2","article-title":"Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis","volume":"7","author":"Wallace","year":"2007","journal-title":"Cardiovasc Toxicol"},{"issue":"758","key":"10.1016\/B978-0-443-18722-3.00035-9_bib83","doi-asserted-by":"crossref","first-page":"eabn8017","DOI":"10.1126\/scisignal.abn8017","article-title":"Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis","volume":"15","author":"Abe","year":"2022","journal-title":"Sci Signal"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib84","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.molcel.2022.03.022","article-title":"Ferroptosis at the intersection of lipid metabolism and cellular signaling","volume":"82","author":"Liang","year":"2022","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib85","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/B978-0-443-18722-3.00035-9_bib86","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132747","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity","volume":"5","author":"Tadokoro","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib87","first-page":"771","article-title":"Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin","volume":"61","author":"Zhou","year":"2001","journal-title":"Cancer Res"},{"issue":"12 Pt A","key":"10.1016\/B978-0-443-18722-3.00035-9_bib88","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.bbadis.2014.09.015","article-title":"Mitochondrial apoptosis-inducing factor is involved in doxorubicin-induced toxicity on H9c2 cardiomyoblasts","volume":"1842","author":"Moreira","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/B978-0-443-18722-3.00035-9_bib89","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00280-009-0932-x","article-title":"Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts","volume":"64","author":"Sardao","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/B978-0-443-18722-3.00035-9_bib90","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-015-1583-9","article-title":"p66Shc signaling is involved in stress responses elicited by anthracycline treatment of rat cardiomyoblasts","volume":"90","author":"Sampaio","year":"2016","journal-title":"Arch Toxicol"},{"issue":"18","key":"10.1016\/B978-0-443-18722-3.00035-9_bib91","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/B978-0-443-18722-3.00035-9_bib92","doi-asserted-by":"crossref","first-page":"e0129303","DOI":"10.1371\/journal.pone.0129303","article-title":"Gene expression profiling of H9c2 myoblast differentiation towards a cardiac-like phenotype","volume":"10","author":"Branco","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2015.05.001","article-title":"Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts","volume":"334","author":"Deus","year":"2015","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib94","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/med.21280","article-title":"Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy","volume":"34","author":"Carvalho","year":"2014","journal-title":"Med Res Rev"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib95","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2010.3492","article-title":"The redox basis of epigenetic modifications: from mechanisms to functional consequences","volume":"15","author":"Cyr","year":"2011","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib96","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mito.2009.09.006","article-title":"Energetics, epigenetics, mitochondrial genetics","volume":"10","author":"Wallace","year":"2010","journal-title":"Mitochondrion"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cmet.2012.06.001","article-title":"Metabolic regulation of epigenetics","volume":"16","author":"Lu","year":"2012","journal-title":"Cell Metab"},{"issue":"1-2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib98","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2012.01.001","article-title":"Connecting threads: epigenetics and metabolism","volume":"148","author":"Katada","year":"2012","journal-title":"Cell"},{"issue":"7472","key":"10.1016\/B978-0-443-18722-3.00035-9_bib99","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature12752","article-title":"The nexus of chromatin regulation and intermediary metabolism","volume":"502","author":"Gut","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.tibs.2017.11.004","article-title":"Spatiotemporal control of acetyl-CoA metabolism in chromatin regulation","volume":"43","author":"Sivanand","year":"2017","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib101","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2013.03.004","article-title":"Influence of metabolism on epigenetics and disease","volume":"153","author":"Kaelin","year":"2013","journal-title":"Cell"},{"issue":"9","key":"10.1016\/B978-0-443-18722-3.00035-9_bib102","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.crvi.2005.08.007","article-title":"Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin","volume":"329","author":"Tokarska-Schlattner","year":"2006","journal-title":"Compt Rend Biol"},{"issue":"8","key":"10.1016\/B978-0-443-18722-3.00035-9_bib103","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.4161\/cbt.7.8.6215","article-title":"A novel role for mitochondria in regulating epigenetic modification in the nucleus","volume":"7","author":"Smiraglia","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib104","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/toxsci\/kfx150","article-title":"Editor\u2019s highlight: the altered dna methylome of chronic doxorubicin exposure in Sprague Dawley rats","volume":"159","author":"Nordgren","year":"2017","journal-title":"Toxicol Sci"},{"issue":"1-2","key":"10.1016\/B978-0-443-18722-3.00035-9_bib105","first-page":"65","article-title":"Effects of S-adenosylmethionine (SAMe) on doxorubicin-induced cardiotoxicity in the rat","volume":"25","author":"Russo","year":"1994","journal-title":"J Med"},{"issue":"7","key":"10.1016\/B978-0-443-18722-3.00035-9_bib106","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0021-9258(17)35746-0","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase","volume":"261","author":"Davies","year":"1986","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/B978-0-443-18722-3.00035-9_bib107","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00109-014-1230-6","article-title":"MitoTimer: a novel protein for monitoring mitochondrial turnover in the heart","volume":"93","author":"Gottlieb","year":"2015","journal-title":"J Mol Med"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib108","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1074\/mcp.M112.021162","article-title":"Metabolic labeling reveals proteome dynamics of mouse mitochondria","volume":"11","author":"Kim","year":"2012","journal-title":"Mol Cell Prot MCP"},{"issue":"6","key":"10.1016\/B978-0-443-18722-3.00035-9_bib109","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1474-9726.2008.00426.x","article-title":"Mitochondrial turnover in liver is fast in vivo and is accelerated by dietary restriction: application of a simple dynamic model","volume":"7","author":"Miwa","year":"2008","journal-title":"Aging Cell"},{"issue":"4","key":"10.1016\/B978-0-443-18722-3.00035-9_bib110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.therap.2022.09.003","article-title":"Evidence-based medicine: friend and foe","volume":"78","author":"Funck-Brentano","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib111","doi-asserted-by":"crossref","first-page":"116405","DOI":"10.1016\/j.taap.2023.116405","article-title":"Natural bioactive compounds-doxorubicin combinations targeting topoisomerase II-alpha: anticancer efficacy and safety","volume":"461","author":"Elfadadny","year":"2023","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib112","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/9781119329725.ch40","article-title":"Mitochondrial toxicity induced by chemotherapeutic drugs","author":"Ferreira","year":"2018","journal-title":"Mitochondr Dysfunct Caused Drugs Environ Toxic"},{"issue":"12","key":"10.1016\/B978-0-443-18722-3.00035-9_bib113","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer","volume":"41","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/B978-0-443-18722-3.00035-9_bib114","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41598-023-29964-4","article-title":"In vitro to clinical translational pharmacokinetic\/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization","volume":"13","author":"Mody","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/B978-0-443-18722-3.00035-9_bib115","first-page":"e37308","article-title":"Efficacy of dexrazoxane in cardiac protection in pediatric patients treated with anthracyclines","volume":"15","author":"Rahimi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/B978-0-443-18722-3.00035-9_bib116","doi-asserted-by":"crossref","first-page":"113903","DOI":"10.1016\/j.biopha.2022.113903","article-title":"Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy","volume":"156","author":"Chen","year":"2022","journal-title":"Biomed Pharmacother"}],"container-title":["Pharmacoepigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780443187223000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780443187223000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:04:01Z","timestamp":1754042641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780443187223000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443187223"],"references-count":116,"URL":"https:\/\/doi.org\/10.1016\/b978-0-443-18722-3.00035-9","relation":{},"subject":[],"published":{"date-parts":[[2025]]}}}